|
Since 1973, John Schlicher has specialized in patents, patent litigation, patent dispute resolution and litigation settlement, patent and technology exploitation by licensing and other business transactions, and antitrust matters involving intellectual property. He has practiced with major patent and general law firms in New York and California. He has also served as inside counsel at a biotech startup, Genentech. He has represented sophisticated companies in many important industries and areas of technology. He has represented companies in more than 25 patent infringement actions and countless other patent, dispute, and licensing matters. He now works with companies, their legal departments, and law firms on projects in his areas of specialty. He provides · Advice on how courts would decide particular issues involving patent validity, scope, infringement, defenses to infringement, damages, and injunctions · Assistance to counsel litigating patent actions on particular issues or phases of litigation in the district courts, Court of Appeals, and Supreme Court · Assistance to companies in resolving patent disputes through private negotiation or ADR processes · Analysis and data on the economic forces underlying decisions to litigate or settle particular patent disputes and actions · Quantitative analysis of appropriate financial terms for settlement and licensing · Advice on the rights and obligations of parties to existing license agreements · Assistance to counsel on licensing strategy and the specific terms of license agreements · Advice on antitrust and misuse issues involving licensing and other transactions involving intellectual property in the United States, the EU and Japan He also serves as an expert on patent, damages and licensing. He has written several published books and dozens of articles analyzing and describing the economic effects of the law and the history of how the law developed. His books and articles have been relied on by the Courts of Appeals for the Federal Circuit, the Seventh Circuit and the district courts. Those books and articles anticipated and influenced changes in important aspects of patent law. He has used economics to help clients make patent decisions, formulate licensing strategy, determine royalties and damages, and settle patent disputes. He has developed empirical data on patent litigation to aid in settlement and licensing decisions. He has taught at Stanford Law School and the School of Law of the University of California, Berkeley. He was educated at Northwestern and Stanford Law School. At Stanford, he was the Research Assistant to Professor William F. Baxter. He is a member of the academic honorary societies for liberal arts, science, and chemistry. He has received awards for his contributions to patent law and science. |
|
John W. Schlicher LAW OFFICE OF JOHN W. SCHLICHER 304 LOWELL LANE W. LAFAYETTE, CALIFORNIA 94549 Tel & fax (925) 284-7675 Cell (925) 818-1484 Email johnschlicher@comcast.net www.johnschlicher.com |
|
Scientific Article, Government Testimony, Professional Activities Books and Articles that influenced and anticipated changes in patent law Injunctions, exhaustion, equivalence, misuse Nonobviousness, on sale, subject matter Comments on schlicher Books and Articles Patent Settlement and licensing An Approach based on Economics and Data EarlyCommentary, Brazil Use in Settlement Negotiations Use in ADR, Settlement Decisions, and Litigation management Patent Damages nine things to Think About before litigating reasonable royalty Damages Nine things wrong with the law on reasonable royalty damages |
|
JOHN W. SCHLICHER |
|
PATENTS, PATENT LITIGATION, PATENT DISPUTE RESOLUTION AND SETTLEMENT, LICENSING, ANTITRUST, LAW AND ECONOMICS |
|
Current Events patent Reform and the America Invents Act Mr. Schlicher’s book on settlement and Licensing is now available from ABA Publishing Link to ABA Store Rossman Award of the Patent and Trademark Office Society Business Method Patents - Bilski FTC Hearings on Damages, Injunctions and the IP Marketplace Declaratory Judgment Actions by Licensees - Medimmune v. Genentech |